Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. (21st December 2017)

• Record Type: Journal Article
• Authors: Taiwo, Babafemi O; Marconi, Vincent C; Berzins, Baiba; Moser, Carlee B; Nyaku, Amesika N; Fichtenbaum, Carl J; Benson, Constance A; Wilkin, Timothy; Koletar, Susan L; Colasanti, Jonathan; Acosta, Edward P; Li, Jonathan Z; Sax, Paul E
• Is Part Of: Clinical infectious diseases. Volume 66:Number 11(2018)
• Page Start: 1794
• Page End: 1797
• Publication Date: 2017-12-21
• Subjects: Dolutegravir -- lamivudine -- 2-drug -- maintenance therapy; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/cix1131
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: In this randomized pilot clinical trial, dolutegravir plus lamivudine was noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. There was no emergence of drug resistance in the participant who experienced virologic failure while receiving dolutegravir plus lamivudine. Clinical Trials Registration: NCT02263326